A system for independent evaluation of clinical prediction models while preserving intellectual property and data privacy

Technical Summary: A System for Independent Evaluation of Clinical Prediction Models

Problem Statement
Clinical prediction models (CPMs) face a critical bottleneck in translating from academic research to clinical practice. While independent external validation is essential for establishing generalisability and safety, it is currently underutilized due to a fundamental conflict between open science and commercial viability.

• The Transparency-Viability Dilemma: Current open science principles (e.g., TRIPOD guidelines) encourage full disclosure of model specifications (coefficients) to enable independent evaluation. However, full disclosure often destroys intellectual property (IP), removing the commercial incentive for developers to fund the substantial regulatory and post-market costs required for medical device certification.
• The Consequence: Developers are forced to choose between obfuscating models (protecting IP but preventing independent validation, as seen with tools like FRAX) or publishing full specifications (enabling validation but risking commercial viability). Consequently, many promising CPMs remain confined to journals, unable to reach clinical implementation.
• Barriers to Evaluation: Existing evaluation methods often require complex data-sharing agreements, specialized infrastructure, or access to raw patient data, creating high barriers for independent researchers.

Methodology: The evaluatr System
The authors propose a novel two-component system designed to enable fully independent evaluation of static CPMs without requiring the sharing of patient data or the disclosure of model parameters. The system consists of a developer-side secure repository and an evaluator-side software package.

1. System Architecture:

   • Developer Side: Developers use a utility function within the evaluatr R package to generate a specification file containing model metadata (structure, variable transformations, baseline hazards, and parameter values). This file is stored in a private, secure GitHub repository. The coefficients are encrypted and transformed prior to storage to prevent reverse-engineering even if the repository is compromised.
   • Evaluator Side: Researchers use the free evaluatr R package. To evaluate a model, they request an access token from the developer. Using this token, the package authenticates, retrieves the encrypted specification from the private repository, and executes the prediction logic locally on the evaluator's dataset.

2. Core Technical Mechanisms:

   • Local Computation: Predictions are computed entirely within the evaluator's local environment. Patient data never leaves the evaluator's secure environment, ensuring data sovereignty and compliance with regulations like GDPR and HIPAA.
   • Decoupled Output: To prevent reverse-engineering of model coefficients and prevent the software from being misused as a clinical decision tool for individual patients, the system does not return a standard prediction table. Instead, it outputs a row-permuted matrix of paired predictions and outcomes. The permutation decouples the prediction from the specific patient's variable values, making it impossible to link a specific prediction back to a specific individual's data or to reconstruct the model parameters via linear algebra.
   • Safety Constraints: The system enforces a minimum dataset size (n=50) to prevent single-patient use and systematic reverse-engineering. It also includes rate limiting on fetch requests.
   • Supported Models: The package currently implements built-in prediction logic for logistic regression, Cox proportional hazards, Weibull accelerated failure time, and multinomial logistic regression. It supports pre-processing steps (e.g., log-transforms, interaction terms) defined as code strings in the specification file.

3. Workflow:

   • The developer registers the model and provides an access token to the evaluator.
   • The evaluator runs the evaluatr package, which fetches the model specification, applies it to their local data, and returns the permuted prediction-outcome matrix.
   • The evaluator uses this matrix to calculate performance metrics (discrimination, calibration, clinical utility) and visualizations (calibration plots, decision curves) without ever seeing the raw coefficients or the unpermuted data.

Key Contributions

• Resolution of the Transparency-Viability Conflict: The system allows developers to retain control over their IP (via encrypted, private storage) while enabling third parties to perform rigorous, independent validation. This creates a viable pathway for CPMs to be both commercially sustainable and scientifically transparent.
• Lowering Barriers to Evaluation: The system requires minimal technical expertise (basic R knowledge), no specialist infrastructure, and eliminates the need for complex data-sharing agreements.
• Alignment with Regulatory Trends: The approach aligns with updated TRIPOD+AI guidelines, which allow for "application programming interfaces" (APIs) in place of direct coefficient disclosure. The evaluatr package functions as this API.
• Auditability and Accountability: The system logs every evaluation event, providing developers with a record of who accessed their model and when, while maintaining evaluator autonomy over their data and reporting.

Results and Claims
The paper presents the system as a conceptual and technical framework rather than a large-scale empirical study of model performance. The "results" are the successful design and implementation of the evaluatr R package and the demonstration of its workflow.

• Functionality: The system successfully computes predictions locally and outputs the permuted matrix, allowing for the calculation of standard performance metrics.
• Security: The architecture ensures that model coefficients remain inaccessible to the evaluator in readable form and that patient data never leaves the local environment.
• Feasibility: The authors demonstrate that the workflow requires only a small number of R commands for both developers and evaluators.

Significance and Claims
The authors claim this system offers a "new paradigm" for clinical prediction modeling.

• Bridging the Gap: It addresses the "false dichotomy" between scientific integrity (transparency) and clinical impact (viability), suggesting that both can be achieved simultaneously.
• Enabling Widespread Evaluation: By removing data access and IP barriers, the system aims to expand the pool of researchers capable of conducting independent evaluations, particularly in resource-constrained settings or underrepresented populations.
• Sustainable Translation: It provides a mechanism for developers to fund the regulatory and implementation lifecycle of CPMs through commercialization while still adhering to the principles of independent scrutiny.
• Regulatory Utility: The authors suggest that regulators and journals could adopt this system as a standard for requiring independent validation, potentially using the public model registry (maintained by the system) as a mechanism for incentivizing or mandating transparency.

The paper concludes by calling for the adoption of this system by developers, journals, and regulators to improve the evidence base for CPMs and facilitate their transition into real-world clinical practice.